Los Angeles, CA—An over-the-counter probiotic that reduces total and low-density lipoprotein cholesterol (LDL-C) levels in adults with moderate hypercholesterolemia has also been shown to lower cholesteryl ester saturated fatty acids, according to data presented at the American Heart Association 2012 Scientific Sessions.
Boston, MA—The amount and the type of omega-3 fatty acids are important for triglyceride lowering. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are distinct omega-3 polyunsaturated fatty acids, but only EPA has been shown to lower triglyceride levels, without increasing low-density lipoprotein cholesterol (LDL-C) in patients with very high triglycerides levels, said Harold Bays, MD, Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center, KY, at the 2012 Cardiometabolic Health Congress.
Munich, Germany—New insights into blood pressure (BP) measurement, prognostic markers, and renal denervation come from a range of hypertension studies presented at the 2012 Congress of the European Society of Cardiology (ESC). Roland E. Schmieder, MD, Professor of Internal Medicine, Nephrology, and Hypertension, University of Erlangen, and Head of the Clinical Research Unit of Hypertension and Vascular Medicine, University Hospital Erlangen-Nürnberg, Germany, presented a tour of these studies.
Munich, Germany—Substantial reductions, by as much as 66%, in the risk of developing hypertension were found in people who adopted healthy lifestyle behaviors in a large prospective population-based cohort study in Finland, the results of which were presented by Pekka Jousilahti, MD, PhD, Research Professor from National Institute for Health and Welfare, Helsinki, Finland, at the 2012 European Society of Cardiology Congress.
Munich, Germany—Dual antiplatelet therapy with an anticoagulant plus clopidogrel was safe and effective at 1 year in patients with atrial fibrillation (AF) or mechanical valves who underwent a percutaneous coronary intervention (PCI), with less bleeding compared with the current guideline-recommended approach of triple therapy that includes aspirin.
Introducing THE LYNX GROUP™: A Global, Strategic Alliance Providing Pivotal and Contemporary Medical Information and Education for All Stakeholders in Healthcare
Monroe Township, NJ and Boston, MA, January 24, 2012 — A formal alliance known as The Lynx Group™ has been established between 4 privately owned medical communication companies each with a unique niche and expertise in the healthcare industry: Engage Healthcare Communications, Green Hill Healthcare Communications, Core Principle Solutions, and Center of Excellence Media.
The Medical Group Management Association (MGMA) makes a practice of taking the pulse of its members. MGMA’s membership includes 21,500 professional administrators in 13,700 organizations, representing 275,000 physicians, who provide more than 40% of the healthcare services in the United States. The results of several surveys conducted this year reflect providers’ escalating panic over:
Among a host of investigational drugs for the treatment of cancer featured during the 2010 meeting of the American Society of Clinical Oncology, the following agents were highlighted as showing great promise.
Crizotinib: Although targeting only a small subset of patients with non–small-cell lung cancer (NSCLC), the investigational agent crizotinib—an oral inhibitor of the ALK gene, which is mutated in about 5% of patients with NSCLC—produced unprecedented response rates in a phase 2 study.
Rising costs pose a significant challenge to the US healthcare system. Congress, public and private payers, and other stakeholders have a significant interest in using comparative effectiveness research to control healthcare costs and support value-based purchasing. Policymakers continue to examine the framework for this research at the national level, while commercial payers are already comparing the effectiveness of products. Widespread use of comparative effectiveness data could have profound implications for manufacturers as well as the entire healthcare system.1
The following findings represent survey responses of medical directors and pharmacy directors (N = 57) from 9 national and many regional health plans from around the country. The survey was conducted during the March 2008 Managed Care Network1 meeting in Orlando, Florida. The percentages shown in the figures represent responses provided by between 49 and 52 of the members who replied to the survey. Additional information can be obtained from Xcenda’s 2008 Oncology Report.2
Page 5 of 7
Results 41 - 50 of 68
Results 41 - 50 of 68